No Data
No Data
Maxim Group Sticks to Their Buy Rating for Dermata Therapeutics (DRMA)
Dermata to Present at the Emerging Growth Conference on April 3, 2024
- Dermata to provide a corporate update followed by a live question and answer session -SAN DIEGO, CA / ACCESSWIRE / March 27, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the
Dermata Therapeutics FY23 EPS $(2.67) Vs $(13.92) YoY
Full Year 2023 Financial ResultsAs of December 31, 2023, the Company had $7.4 million in cash and cash equivalents, compared to $6.2 million as of December 31, 2022. The increase in cash and cash equi
Dermata Therapeutics: Unveiling Recent Financial Performance
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
- Initiated enrollment of DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial in Q4 2023 -- Raised $9.1 million in gross proceeds from three financings completed in 2023 -- Rec
Dermata to Present at the Emerging Growth Conference on February 7, 2024
- Company to provide a corporate overview followed by a live question and answer session -SAN DIEGO, CA / ACCESSWIRE / February 1, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Derma
No Data